Vir Stock Craters On Weak Results For Glaxo-Partnered Covid Treatment

Vir Stock Craters On Weak Results For Glaxo-Partnered Covid Treatment

Emerging data cast doubt on the effectiveness of Vir Biotechnology and GlaxoSmithKline's Covid-19 treatment, leading Vir stock to plummet Wednesday. Shares fell more than 27%.